

## Editorial

3

*Gregor Fuhrmann*

### Extracellular vesicles – what's in it for us?

## EV societies

8, 16, 46

## Meet the researcher

10

### A few questions to Dr Clotilde Théry, INSERM, Institut Curie, Paris

Clotilde Théry obtained her PhD in 1991 at College de France, Paris. She then was a postdoc at Oxford University and Columbia University. In 2007, Clotilde started her research group "Extracellular Vesicles, Immune responses and Cancer" at Institut Curie. She is the current president of the International Society for Extracellular Vesicles.

## Opinion paper

12

*Marie Mosbach, Elke Pogge von Strandmann and Christian Preußner*

### RNAs and extracellular vesicles – keeping up the appearances

Since the advent of extracellular vesicle (EV) research in the last decade, these particles have been associated with RNAs. Traded as promising new biomarkers, RNA transport vehicles, or ultimately as potential therapeutic RNA delivery vehicles. However, this view is currently undergoing a change in which RNA may no longer be a major component of EVs. In this short opinion paper, we would like to encourage a reconsideration of our view on EVs and RNAs and open it up to new thoughts.

## The exRNA consortium

17

*Karl-Heinz Kogel, Albrecht Bindereif, Michael Feldbrügge,  
Vera Göhre, Alexander Goesmann, Julia Kehr,  
Ralph Panstruga, Christian Preußner, Silke Robatzek and Arne Weiberg*  
**Establishment of a DFG-funded research group on the topic of  
plant-microbe communication through extracellular RNA**

The exRNA consortium, a team of researchers funded by the Deutsche Forschungsgemeinschaft (DFG), addresses crucial aspects of cross-kingdom RNA interference (ckRNAi) and RNA application in plant protection, mainly focusing on mechanistic considerations and application efficiencies.

## Research Training Group Tumor Secretome

24

*Elke Pogge von Strandmann, Rolf Müller and Karen Schwabe*

### Focus on the tumor secretome: basic and translational research within the research training group 2573

The Research Training Group (RTG) focuses on several tumor entities that are critically dependent on the TME such as ovarian cancer, pancreatic cancer and acute myeloid leukemia. Of particular interest is the role of NF- $\kappa$ B and p53-regulated secretome components, including EVs, that modulate the plasticity of tumor-associated immune cells, nonmalignant bystander cells, cancer cell invasion, metastasis, and resistance to therapy.